keyword
MENU ▼
Read by QxMD icon Read
search

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGIST

keyword
https://www.readbyqxmd.com/read/29320643/2017-american-association-of-clinical-endocrinologists-endocrine-society-update-on-transgender-medicine-case-discussions
#1
Vin Tangpricha, Sabine E Hannema, Michael S Irwig, Walter J Meyer, Joshua D Safer, Wylie C Hembree
OBJECTIVE: Increased numbers of transgender and gender-nonconforming people are presenting to physicians in the United States and abroad due to increased public recognition and acceptance and increased access to healthcare facilities. However, there are still gaps in medical knowledge among endocrinologists and other health care professionals. The purpose of these cases is to present several common clinical vignettes of transgender people presenting in an office setting that illustrate some of the key recommendations of the Endocrine Society's revised Endocrine Treatment of Gender Dysphoria/Gender Incongruent Persons guidelines, cosponsored by the American Association of Clinical Endocrinologists...
December 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29320641/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-position-statement-on-testing-for-autonomic-and-somatic-nerve-dysfunction
#2
Aaron I Vinik, Pauline M Camacho, Jaime A Davidson, Yehuda Handelsman, Howard M Lando, Anne L Leddy, Sethu K Reddy, Richard Cook, Vicenza Spallone, Solomon Tesfaye, Dan Ziegler
This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician...
December 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29285458/sodium-glucose-cotransporter-2-inhibitors-moving-beyond-the-glycemic-treatment-goal
#3
REVIEW
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia
Revelations of the multifactorial pathogenesis of type 2 diabetes mellitus (T2DM) that extend beyond the role of insulin and glucose utilization have been crucial in redefining the treatment paradigm. The focus of treatment is currently directed towards achieving wide-ranging targets encompassing the management of cardiovascular comorbidities that have been evidenced as indispensable aspects of T2DM. While most currently prescribed antihyperglycemic agents have little or no effect on reducing cardiovascular risks, some have been associated with undesirable effects on common risk factors such as weight gain and cardiovascular sequelae...
November 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29275030/testosterone-and-cardiovascular-health
#4
REVIEW
Andrew Elagizi, Tobias S Köhler, Carl J Lavie
There is an ongoing debate in the medical community regarding the effects of testosterone on cardiovascular (CV) health. For decades, there has been conflicting evidence regarding the association of endogenous testosterone levels and CV disease (CVD) events that has resulted in much debate and confusion among health care providers and patients alike. Testosterone therapy has become increasingly widespread, and after the emergence of studies that reported increased CVD events in patients receiving testosterone therapy, the US Food and Drug Administration (FDA) released a warning statement about testosterone and its potential risk regarding CV health...
December 20, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29190135/aace-ace-position-statement-on-the-use-of-follow-on-biologics-and-biosimilars-for-endocrine-diseases
#5
Vivian A Fonseca, Zachary T Bloomgarden, Samuel Dagogo-Jack, George Grunberger, Daniel Einhorn, Alan J Garber, Yehuda Handelsman, Irl B Hirsch, Guillermo E Umpierrez
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician...
November 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29167761/european-thyroid-association-guidelines-for-ultrasound-malignancy-risk-stratification-of-thyroid-nodules-in-adults-the-eu-tirads
#6
Gilles Russ, Steen J Bonnema, Murat Faik Erdogan, Cosimo Durante, Rose Ngu, Laurence Leenhardt
Thyroid ultrasound (US) is a key examination for the management of thyroid nodules. Thyroid US is easily accessible, noninvasive, and cost-effective, and is a mandatory step in the workup of thyroid nodules. The main disadvantage of the method is that it is operator dependent. Thyroid US assessment of the risk of malignancy is crucial in patients with nodules, in order to select those who should have a fine needle aspiration (FNA) biopsy performed. Due to the pivotal role of thyroid US in the management of patients with nodules, the European Thyroid Association convened a panel of international experts to set up European guidelines on US risk stratification of thyroid nodules...
September 2017: European Thyroid Journal
https://www.readbyqxmd.com/read/29162582/standardizing-clinically-meaningful-outcome-measures-beyond-hba1c-for-type-1-diabetes-a-consensus-report-of-the-american-association-of-clinical-endocrinologists-the-american-association-of-diabetes-educators-the-american-diabetes-association-the-endocrine
#7
REVIEW
Gina Agiostratidou, Henry Anhalt, Dana Ball, Lawrence Blonde, Evgenia Gourgari, Karen N Harriman, Aaron J Kowalski, Paul Madden, Alicia H McAuliffe-Fogarty, Molly McElwee-Malloy, Anne Peters, Sripriya Raman, Kent Reifschneider, Karen Rubin, Stuart A Weinzimer
OBJECTIVE: To identify and define clinically meaningful type 1 diabetes outcomes beyond hemoglobin A1c (HbA1c) based upon a review of the evidence, consensus from clinical experts, and input from researchers, people with type 1 diabetes, and industry. Priority outcomes include hypoglycemia, hyperglycemia, time in range, diabetic ketoacidosis (DKA), and patient-reported outcomes (PROs). While priority outcomes for type 1 and type 2 diabetes may overlap, type 1 diabetes was the focus of this work...
December 2017: Diabetes Care
https://www.readbyqxmd.com/read/29156187/guideline-recommendations-for-obesity-management
#8
REVIEW
Donna H Ryan, Scott Kahan
It is an obligation for all health care providers to participate in obesity management. This article discusses obesity guidelines from The Obesity Society; the Endocrine Society; and the American Association of Clinical Endocrinologists. It reviews and compares findings and recommendations across these guidelines, identifies areas of controversy and concordance, and suggests how primary care practices may make use of the most appropriate recommendations for their circumstances.
January 2018: Medical Clinics of North America
https://www.readbyqxmd.com/read/29106816/insulin-glargine-300-u-ml-is-associated-with-less-weight-gain-while-maintaining-glycemic-control-and-low-risk-of-hypoglycemia-compared-with-insulin-glargine-100-u-ml-in-an-aging-population-with-type-2-diabetes
#9
Medha N Munshi, Jasvinder Gill, Jason Chao, Elena V Nikonova, Meenakshi Patel
OBJECTIVE: Assess efficacy, hypoglycemia and weight gain in patients with type 2 diabetes (T2D) treated with insulin glargine 300 U/mL (Gla-300) or 100 U/mL (Gla-100) across different age groups. METHODS: Pooled data were generated for patients randomized to Gla-300 or Gla-100 in the EDITION 2 (NCT01499095) and 3 (NCT01676220) studies. In four age groups (<55, ≥55 to <60, ≥60 to <65, ≥65 years), glycated hemoglobin A1C (A1C), percentage of patients reaching A1C <7...
November 6, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28978219/epidemiology-and-management-of-hyperlipidemia
#10
Samantha Karr
Cardiovascular disease (CVD) is the leading cause of death among adults in the United States, and people with hyperlipidemia are at roughly twice the risk of developing CVD as compared to those with normal total cholesterol levels.1 Patients with familial hypercholesterolemia (FH) have an even greater risk of developing CVD at an earlier age; therefore, early detection and treatment are imperative to reduce cardiovascular events and premature death. Statins are the mainstay treatment for hyperlipidemia; however, the limitations of statins include treatment resistance, intolerance due to adverse events, and a lack of adherence which contribute to poor outcomes...
June 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28936195/diagnostic-yield-and-accuracy-of-different-metabolic-syndrome-criteria-in-adult-patients-with-epilepsy
#11
Lucas Scotta Cabral, Pedro Abrahim Cherubini, Marina Amaral de Oliveira, Larissa Bianchini, Carolina Machado Torres, Marino Muxfeldt Bianchin
INTRODUCTION: Metabolic syndrome (MetS) is an emergent problem among patients with epilepsy. Here, we evaluate and compare the diagnostic yield and accuracy of different MetS criteria among adult patients with epilepsy to further explore the best strategy for diagnosis of MetS among patients with epilepsy. MATERIALS AND METHODS: Ninety-five epileptic adults from a tertiary epilepsy reference center were prospectively recruited over 22 weeks in a cross-sectional study...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28920749/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-disease-state-commentary-managing-thyroid-tumors-diagnosed-as-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features
#12
Zubair W Baloch, R Mack Harrell, Elise M Brett, Gregory Randolph, Jeffrey R Garber
This commentary summarizes the history and reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclei (NIFTP). It reviews the salient histopathologic features that are based on immunohistochemical and molecular profiles and serve as inclusion and exclusion criteria. The authors also provide their own point of view regarding the practical issues and possible concerns that may be raised by both clinicians and patients based on the diagnosis of NIFTP. ABBREVIATIONS: AACE = American Association of Clinical Endocrinologists EFVPTC = encapsulated FVPTC FNA = fine-needle aspiration FVPTC = follicular variant of papillary thyroid carcinoma NIFTP = noninvasive follicular thyroid neoplasm with papillary-like nuclear features PTC = papillary thyroid carcinoma...
September 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28834286/american-association-of-diabetes-educators-2017
#13
Ann M Carracher, Payal H Marathe, Kelly L Close
Ann M. Carracher, Payal H. Marathe, and Kelly L. Close are of Close Concerns (http://www.closeconcerns.com), a healthcare information company focused exclusively on diabetes and obesity care. Close Concerns publishes Closer Look, a periodical that brings together news and insights in these areas. Each month, the Journal of Diabetes includes this News feature, in which Carracher, Marathe, and Close review the latest developments relevant to researchers and clinicians.
August 18, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28686557/the-biopsychosocial-model-40-years-of-application-in-psychiatry
#14
G Papadimitriou
In 1977, the American pathologist and psychiatrist George Engel (1913-1999) published in the Journal Science his paper "TheIn 1977, the American pathologist and psychiatrist George Engel (1913-1999) published in the Journal Science his paper "Theneed for a new medical model: A challenge for biomedicine", introducing the term Biopsychosocial Model. This model basedon the results of Engel's studies in ulcerative colitis, depression and psychogenic pain, constituted a challenge for biomedicineand the biomedical model...
April 2017: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28671443/subclinical-hyperthyroidism-when-to-consider-treatment
#15
REVIEW
Ines Donangelo, Se Young Suh
Subclinical hyperthyroidism is defined by a low or undetectable serum thyroid-stimulating hormone level, with normal free thyroxine and total or free triiodothyronine levels. It can be caused by increased endogenous production of thyroid hormone (e.g., in Graves disease, toxic nodular goiter, or transient thyroiditis), by administration of thyroid hormone to treat malignant thyroid disease, or by unintentional excessive replacement therapy. The prevalence of subclinical hyperthyroidism in the general population is about 1% to 2%; however, it may be higher in iodinedeficient areas...
June 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28655595/diabetes-of-the-exocrine-pancreas-american-diabetes-association-compliant-lexicon
#16
Maxim S Petrov
Multidisciplinary teams, including gastroenterologists, endocrinologists, surgeons, dietitians, primary care physicians, and other health professionals, are involved in management of individuals with diabetes of the exocrine pancreas (DEP). This necessitates introduction of a uniform terminology to ensure proper communication and reporting. Because DEP is a form of secondary diabetes mellitus, it makes sense to align the evolving DEP lexicon with nomenclature and diagnostic standards advocated by a world leading professional body in the field of diabetes such as the American Diabetes Association...
July 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/28650892/the-2017-hormone-therapy-position-statement-of-the-north-american-menopause-society
#17
(no author information available yet)
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence...
June 22, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28650869/the-2017-hormone-therapy-position-statement-of-the-north-american-menopause-society
#18
(no author information available yet)
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence...
July 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28650348/an-update-on-type-2-diabetes-management-in-primary-care
#19
Jeffrey Waddell
Diabetes mellitus is a chronic disease impacting glucose metabolism. Type 2 diabetes mellitus (T2DM) stems from the inability of the body to utilize endogenous insulin properly. Approximately 90% to 95% of newly diagnosed cases of diabetes are T2DM. This article focuses on the initial treatment of T2DM based on the 2017 American Association of Clinical Endocrinologists and the American College of Endocrinology clinical practice guidelines. The 2017 update includes changes and additions regarding psychosocial management, physical activity, surgery, and hypoglycemia...
August 17, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28606343/pharmacologic-management-of-type-2-diabetes-mellitus-available-therapies
#20
REVIEW
James Thrasher
Choices for the treatment of type 2 diabetes mellitus (T2DM) have multiplied as our understanding of the underlying pathophysiologic defects has evolved. Treatment should target multiple defects in T2DM and follow a patient-centered approach that considers factors beyond glycemic control, including cardiovascular risk reduction. The American Association of Clinical Endocrinologists/American College of Endocrinology and the American Diabetes Association recommend an initial approach consisting of lifestyle changes and monotherapy, preferably with metformin...
July 1, 2017: American Journal of Cardiology
keyword
keyword
114563
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"